Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
RESEARCH TOOLSreports
Inhibikase Therapeutics (IKT) Stock Price & Analysis
94 Followers
IKT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.79 - $4.35
Previous Close$1.73
Volume46.75K
Average Volume (3M)64.74K
Market Cap
$11.20M
Enterprise Value-$9.43M
Total Cash (Recent Filing)$20.94M
Total Debt (Recent Filing)$297.94K
Price to Earnings (P/E)-0.5
Beta0.62
Next Earnings
Aug 12, 2024EPS Estimate
-$0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.37
Shares Outstanding6,476,844
10 Day Avg. Volume100,127
30 Day Avg. Volume64,736
Standard Deviation0.31
R-Squared0.04
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.75
Price to Sales (P/S)90.77
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-38.58
Enterprise Value/Gross Profit-76.41
Enterprise Value/Ebitda0.48
Forecast
1Y Price Target
$17.50Price Target Upside911.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Inhibikase Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial MilestonesThe Phase 2a study of Risvodetinib is advancing, focusing on both motor and non-motor Parkinson's symptoms and the reduction of alpha-synuclein aggregates, which could indicate a disease-modifying effect.
Drug Development ProgressRisvodetinib, a promising treatment for Parkinson’s disease, shows strong potential with over 25 times stronger inhibition of c-Abl than its predecessor, and modifications for enhanced brain penetration and selectivity.
Regulatory AdvancementsIkT-001Pro, targeting multiple oncology indications, has completed bioequivalence studies, with the FDA providing clear requirements for NDA filing, marking a definitive step forward in the drug’s development process.
Bears Say
Financial PerformanceInhibikase reported year-end results with a significant net loss, which may raise concerns about its financial stability.
Product ValuationAnalysts have excluded IkT-001Pro from their valuation, suggesting uncertainty about the product's potential to contribute to Inhibikase's financial growth.
RisksInhibikase faces multiple challenges including commercial, regulatory, clinical, and intellectual property risks that could impact its future performance.
---
Ownership Overview
83.12%
Insiders
1.84% Mutual Funds
0.56% Other Institutional Investors
14.48% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IKT FAQ
What was Inhibikase Therapeutics’s price range in the past 12 months?
Inhibikase Therapeutics lowest stock price was $0.79 and its highest was $4.35 in the past 12 months.
What is Inhibikase Therapeutics’s market cap?
Currently, no data Available
When is Inhibikase Therapeutics’s upcoming earnings report date?
Inhibikase Therapeutics’s upcoming earnings report date is Aug 12, 2024 which is in 84 days.
How were Inhibikase Therapeutics’s earnings last quarter?
Inhibikase Therapeutics released its earnings results on May 16, 2024. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.79 by $0.06.
Is Inhibikase Therapeutics overvalued?
According to Wall Street analysts Inhibikase Therapeutics’s price is currently Undervalued.
Does Inhibikase Therapeutics pay dividends?
Inhibikase Therapeutics does not currently pay dividends.
What is Inhibikase Therapeutics’s EPS estimate?
Inhibikase Therapeutics’s EPS estimate is -$0.57.
How many shares outstanding does Inhibikase Therapeutics have?
Inhibikase Therapeutics has 6,476,844 shares outstanding.
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Inhibikase Therapeutics reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.79. Following the earnings report the stock price went down -11.558%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
Currently, no hedge funds are holding shares in IKT
---
Inhibikase Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (911.56% Upside)
$17.50 (911.56% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.31%
12-Months-Change
Fundamentals
Return on Equity
-119.64%
Trailing 12-Months
Asset Growth
-60.70%
Trailing 12-Months
Company Description
Inhibikase Therapeutics
Inhibikase Therapeutics Inc is a clinical stage pharmaceutical company developing therapeutics for Parkinson's Diseases and related disorders inside and outside the brain. Its pipeline product, IkT-148009, targets underlying disease mechanisms to reverse the course of Parkinson's disease and the GI complications of Parkinson's disease.
---
IKT Earnings Call
Q1 2024
0:00 / 0:00
---
IKT Stock 12 Month Forecast
Average Price Target
$17.50
▲(911.56% Upside)
Technical Analysis
Best Analysts Covering IKT
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-18.71%
reiterated a buy rating 3 months ago
Copying Edward White's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -18.71% per trade.
---